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Abstract 
Left ventricular hypertrophy (LVH) is commonly present in patients with hypertension (HT). Angiotensin-II and 
chronic stimulation of β1-adrenergic receptors (β1-AR) contribute to LVH  progression  in hypertensive 
patients. Angiotensin-II Receptor Blocker (ARB) has been shown  effectively regression  left ventricular mass 
index. The aim of this study was to identify the efficacy of  Bisoprolol reducing  left ventricular hypertrophy 
(LVH) in Arg389Arg hypertensive patients receiving ARB. This prospective pre-post test cohort study included 
39 male hypertensive patients who met the inclusion criteria. Patients underwent 24-hour Ambulatory Blood 
Pressure Monitoring (ABPM) procedures, echocardiographic examination to assess LVH pre-post 6 months of 
ARB treatment. Regimen was optimized based on office blood pressure. Arg389Gly β1-AR polymorphism was 
examined using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) 
method and confirmed by sequenzing method.  
------------------------------------------------------------------------ 
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As the results, frequency of Arg389Arg and  Arg389Gly/Gly389Gly were 46.15% and 53.85%, respectively. In 
hypertensive patients with LVH, frequency of Arg389Arg and  Arg389Gly/Gly389Gly were 23.08% and 
17.95%, respectively.  The reduction of LVMI, LVmass, or RWT (Relative Wall Thickness) after 6-months of 
ARB treatment (Valsartan or Telmisartan) in Arg389Arg or Arg389Gly/Gly389Gly hypertensive patients were 
not significant. However, Bisoprolol reduce LVMI from 137.50±22.62 to 63.67±28.08 g/m2 (p=0.028), LVmass 
240.17±40.14 to 130.67±22.39 gram (p=0.028), and RWT 0.49±0.08 to 0.36±0.11 in Arg389Arg hypertensive 
patients receiving ARB. Our study conclude that ARB treatment for 6-months did not reduce significantly 
LVMI, LVmass, and RWT in both Arg389Arg and Arg389Gly/Gly389Gly hypertensive patients. β1-AR 
blocker (Bisoprolol) reduce LVH in Arg389Arg hypertensive patients receiving ARB significantly. 
Keywords: left ventricular hypertrophy; Arg389Arg; angiotensin-II receptor blocker. 
1. Introduction  
Left ventricular hypertrophy (LVH) is commonly present in hypertensive (HT) patients. It could strongly predict 
cardiovascular mortality and morbidity [1-3], and was associated with increased incidence of atrial fibrillation, 
left ventricular dysfunction, and heart failure [4-6]. 
Experimental and clinical evidence suggests that angiotensin-II contributes as a significant pathway to the 
progress of hypertrophy and left ventricular remodeling in hypertension through apoptosis of cardiomyocyte, 
myocardial fibrosis, and changes in wall composition and intramiocard artery geometry in the hypertrophied left 
ventricle [7]. There were several meta-analyses concerning the effect of  5 different classes of antihypertensive 
drugs on LVH [8-10]. Although their conclusions had some differences, all of them agreed on a point that 
regression was worse with beta-blockers and better with angiotensin-converting enzyme inhibitor (ACEI) or 
angiotensin receptor blockers (ARBs). On the basis of these previous clinical researches and meta-analyses, the 
expert consensus document on hypertension from American suggested that ACEI or ARBs should generally be 
used in hypertensive patients with LVH [11]. 
The human β1 adrenergic receptor (ADRB1) is a member of the family of seven-transmembrane G-protein-
coupled receptors, and expressed in cardiac myocytes [12]. Chronic stimulation of ADRB1 results in cardiac 
hypertrophy and heart failure [13]. The expression of ADRB1 RNA has been reported to be significantly higher 
in spontaneously hypertensive rat [14]. It also has been shown that chronic stimulation of cardiac ADRB1 has 
detrimental effects on the heart in the transgenic models with cardiac over-expression of ADRB1 [15,16]. The 
ADRB1 gene has been cloned in 1987 and localized to chromosome 10 [17]. Two common polymorphisms, 
Arg389-Gly and Gly49Ser, were identified in 1999 [18]. Arg389Gly is located in the intracellular cytoplasmic 
tail near the seventh transmembrane region of the receptor, which is a putative protein binding domain. The 
Arg389 variant mediates a higher isoproterenol-stimulated adenylate cyclase activity than does Gly389 variant 
in vitro [19]. The Ser49Gly polymorphism is located in the extra-cellular amino-terminal region of the receptor, 
but no studies have been published on the potential functional consequences of this polymorphism [20]. The 
Arg389Gly polymorphism has been shown to be associated with heart failure,  acute myocardial infarction, 
hypertensive status and the variability of left ventricular remodeling and blood pressure in response to beta-
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blockade [21-26]. Patients carrying the Arg389Arg genotype had an increase significantly  in the left ventricular 
septal thickness; left ventricular posterior wall thickness; left ventricular mass index; and relative wall thickness 
as compared with those carrying genotypes Arg389Gly and Gly389Gly [27]. We hypothesized that Bisoprolol 
reduce left ventricular hypertrophy (LVH) in Arg389Arg hypertensive patients receiving ARB. 
The aim of this study was to identify the efficacy of  Bisoprolol reducing  left ventricular hypertrophy (LVH) in 
Arg389Arg hypertensive patients receiving ARB. 
2. Materials and Methods  
The observational cohort of prospective pre-post test studies from January 1st, 2014 to June 9th, 2017 included 
39 patients with inclusion criteria: men; age 40-75 years old; hypertension (JNC-7) criteria [28] as diastolic 
blood pressure equal to or over 90 mmHg and/or systolic blood pressure equal to or over 140 mmHg (average of 
2 measurements)) that has not/ not been in antihypertensive treatment or dropped out of antihypertensive 
treatment for at least 2 weeks or untolerable to Angiotensin Converting Enzyme (ACE) Inhibitor; have health 
insurance; have high adherence (score 8 in answering the Morisky Medication Adherence Scale (MMAS) 
questionnaire in therapy; and willing to sign research informed consent. The exclusion criterias included severe 
disease that may limit longterm survival such as diabetes, hypertrophic cardiomyopathy, valvular heart diseases, 
pulmonary hypertension, coronary heart diseases, left heart failure stage C or D, impaired renal function, 
impaired liver function, active bleeding, or patients undergoing corticosteroid treatment based on medical 
history, physical examination, electrcardiography, echocardiography and biochemical measurements. All 
investigators were trained at the Cardiovascular Institute, Malang Saiful Anwar Hospital. Patients underwent 24-
hour Ambulatory Blood Pressure Monitoring (ABPM) procedure, echocardiogram with M-mode using 
parasternal long axis (PLAX) view to measure LVMI, LVmass, RWT as LVH parameters before and after 6 
months of ARB-based therapy and regimens during follow-up was optimized according office blood-pressure. 
The examination of the β1-adrenergic receptor polymorphism of Arg389Gly begins with DNA isolation; 
followed by Polymerase Chain Reaction (PCR) using ddH2O 6μl, PCR mix 10 μl, 1μl DMSO, 1μl forward, 1μl 
reverse, 1μl DNA through pre-denaturation stage 95ºC for 3 min, denaturation 95ºC for 30 seconds, annealing 
60ºC for 30 seconds , extension 72ºC for 30 seconds, post-extension 72ºC for 10 minutes with 530bp target 
amplikon. Finally, Restriction Fragment Length Polymorphism (RFLP) using BcgI 2 unit enzyme; 1μl buffer; 
SAM 0,5μl; ddH2O 4,5μl; 3μl DNA was done and RFLP results confirmed by sequenzing method. Processing 
and data analysis statistical tests were performed using IBM SPSS statistic version 18.0. The Hardy-Weinberg 
balance was tested on all polymorphisms by comparing genotypes in the study subjects and genotype 
predictions using χ2 tests. Numerical variables are shown in the standard deviation ± form. The log 
transformation was performed on echocardiography results to improve the normality of the data. Different tests 
were evaluated with student t-test for normal distributed data, while the Mann-Whitney different test was 
performed for abnormally distributed data. Two tailed P <0.1 is considered statistically significant. 
3. Results  
3.1 Characteristics of Research Subjects 
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From January 2014 - June 2017, 39 male hypertensive patients who met the inclusion criteria were found with 
an average age of  56.4 years old. There were 18 patients with homozygous Arg389 (46.15%), and Gly389 
carriers were 21 patients (53.85%) in which 3 patients were homozygous Gly389 (7.69%) (Table 1). Patient 
population was classified by genotype Arg389Arg (AA) and Arg389Gly/Gly389Gly (AG/GG). 
Table 1: Baseline Characteristics of Research Subjects 
Variable AA (n=18) AG / GG (n=21) P value 
Age (years) 58.6 ± 8.46 54.5 ±11.33 0.247 
Durations of  
Hipertensi (years) 
8.6 ± 6.84 8.6 ± 7.43 0.745 
BMI (kg/m2) 25.1 ± 4.83 26.4 ± 3.75 0.096 
SBP (mmHg) 139.8 ± 15.25  141.5 ± 16.79 0.751 
DBP (mmHg) 88.4 ± 12.28 89.1 ± 12.21 0.864 
LV ST (mm) 1.2 ± 0.35 1.2 ± 0.32 0.374 
LV PWT (mm) 1.3 ± 0.26 1.2 ± 0.28 0.376 
LVMi (g/m2) 119.9 ± 47.25 118.0 ± 51.18 0.673 
LVMass  204.4 ± 82.01 212.5 ± 90.12 1.000 
RWT (%) 0.6 ± 0.16 0.5 ± 0.16 0.100 
 
BMI, body mass index; SBP, systolic blood pressure;DBP, diastolic blood pressure; LV ST, left ventricular 
septal thickness; LV PWT, left ventricular posterior wall thickness; LVMi, left ventricular mass index; LV 
mass, left ventricular mass; RWT, relative wall thickness. 
3.2 Analysis Variable Research 
3.2.1  Reduction Variables before and After ARB-Based Treatment in  LVH-Hypertensive Patients Group 
with Genotype of Adrenergic Receptors β1(Arg389Arg and Arg389Gly/Gly389Gly) 
Sixteen of the 39 samples that completed this study met the LVH echocardiography criterias (LVMi value 
>115g/m2 and/ or LVmass >224 grams).  
The follow-up of 6 months of ARB-based treatment in hypertensive patients with LVH showed a reduce in 
BMI, SBP, DBP, LVMi, LVmass, and RWT levels (Table 2). 
In the LVH group with Arg389Arg genotype, there was significant difference of LVMi (p=0,038) and LVmass 
(p=0,027) values before and after 6 months follow-up of ARB-based treatment (Figure 1). In the LVH group 
with the Arg389Gly/Gly389Gly genotype, there was significant difference of LVmass (p=0,010) on before and 
after 6 months follow-up of ARB-based treatment (Figure 2). 
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Table 2: Parameters of Reduction Variables before and After ARB-Based Treatment in  LVH-Hypertensive 
Patients Group with Genotype of Adrenergic Receptors β1 
Variable LVH-Hypertensive Patients Group 
Genotype Arg389Arg (n=9) Genotype Arg389Gly/ Gly389Gly (n=7) 
Before Treatment 6-months  
follow up 
( AfterTreatment) 
Before Treatment 6-months  
follow up 
( After-Treatment) 
BMI (kg/m2) 
SBP (mmHg) 
DBP (mmHg) 
LVMi (g/m2) 
23.9 ± 2.40 
142.9 ± 12.37 
90.7 ± 10.40 
156.3 ± 36.20 
23.0 ± 2.10 
137.5 ± 14.14 
86.5 ± 13.02 
102.0 ± 56.79* 
27.2 ± 4.77 
156.0 ± 16.20 
94.4 ± 16.94 
178.6 ± 42.48 
27.7 ± 4.30 
144.8 ± 15.34 
85.4 ± 9.54 
142.3 ± 73.17 
LVMass  
RWT (%) 
267.9 ± 58.79 
0.6 ± 0.12 
186.4 ± 81.06* 
0.5 ± 0.20 
317.3 ± 79.00 
0.5 ± 0.13 
179.8 ± 44.20* 
0.5 ± 0.16 
*p < 0,05  
  
 
Figure 1: Parameter graph of reduction variables before and after ARB-based treatment in Arg389Arg 
hypertensive patients with LVH 
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Figure 2: Parameter graph of reduction variables before and after ARB-based treatment in 
Argota9Gly/Gly389Gly hypertensive patients with LVH 
 
3.2.2 Reduction Variables before and After ARB-Based Treatment in  Non LVH-Hypertensive Patients 
Group with Genotype of Adrenergic Receptors β1  
Twenty-three of the 39 samples that completed this study did not meet the LVH echocardiography criteria 
(LVMi values ≤115 g / m2 and or LVmass ≤ 224 grams).  
Results of a 6-month follow-up of ARB-based treatment in the hypertensive patient without LVH group showed 
an increase in SBP, DBP, LVMi, and LVmass values in the Arg389Arg genotype group. While in the genotype 
group Arg389Gly / Gly389Gly showed average changes before and after therapy tended to be constant (Table 
3). 
Table 3: Parameters of Reduction Variables before and after ARB-Based Treatment in Non-LVH Hypertensive 
Patients Group with Genotype of Adrenergic Receptors β1 
Variable Non-LVH Group (n=23) 
Arg389Arg (n=9) Arg389Gly/Gly389Gly (n=14) 
Before Treatment 6 months  
Follow up 
(After Treatment) 
Before Treatment 6 months  
Follow up 
(After Treatment) 
BMI (kg/m2) 
SBP (mmHg) 
DBP (mmHg) 
LVMi (g/m2) 
LVMass  
RWT (%) 
25.5 ± 4.40 
136.7 ± 17.88 
86.1 ± 14.16 
83.4 ± 21.10 
141.0 ± 42.17  
0.6 ± 0.19 
25.33 ± 3.94 
141.4 ± 19.00 
89.2 ± 12.14 
103.1 ± 23.96 
179.2 ± 51.47 
0.5 ± 0.26 
24.9 ± 2.91 
134.2 ± 11.90 
86.4 ± 8.61 
87.8 ± 15.17 
160.1 ± 27.24 
0.5 ± 0.17 
25.5 ± 2.45 
134.9 ± 11.56 
83.7 ± 8.99 
89.5 ± 23.76 
153.1 ± 60.9 
0.5 ± 0.17 
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Figure 3: Parameter graph of reduction variables before and after ARB-based treatment in Arg389Arg 
hypertensive patients without LVH 
 
Figure 4: Parameter graph of reduction variables before and after ARB-based treatment in 
Arg389Gly/Gly389Gly hypertensive patients without LVH 
 
3.2.3 Role of Treatment Based on Angiotensin-II Receptor Blocker (ARB) and Combination with Beta-
Blocker in Reduce  Left Ventricular Hypertrophy  
Analysis of ARB impact on LVMi reduction variable parameter; LVmass; and RWT were divided into three 
categorical groups, ie the variable group of ARB telmisartan, valsartan, and combination ARB and beta-blocker 
groups to LVH reduction divided into Arg389Arg (AA) and Arg389Gly/Gly389Gly (AG/GG) groups. Valsartan 
or telmisartan administration in the group of patients with positive left ventricular reduction in genotype AA or 
AG/GG did not show significant relationship (Table 4). Administration of ARB with beta-blocker in the group 
of patients who had left ventricular mass reduction showed significant association with LVMi, LVmass, and 
RWT reduction in the genotype AA group with p-value LVMi 0.028; p-value LVmass 0,028; and p-value RWT 
0.027. While giving ARB with beta-blocker in genotype group AG/GG did not show significant relationship. 
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Table 4: LVH Reduction Based on Antihypertensive Treatment 
 Reduction LVH in Hypertensive Patients  
 Arg389Arg (n=12)  Arg389Gly/Gly389Gly (n=10)  
Variable Before 
Treatment 
6-Months 
After 
Treatment 
p Before 
Treatment 
6-Months 
After 
Treatment 
p 
ARB  
Telmisartan  
(n = 6) 
 
Arg389Arg (n=4) 
  
Arg389Gly/Gly389Gly (n=2) 
 
SBP 
DBP 
LVMI 
LVMass 
RWT 
138,68 ± 7,18 
87,60 ± 11,98 
131,00 ± 16,83 
237,25 ± 35,22 
0,52 ± 0,05 
140,25 ± 22,61 
90,03 ± 19,64 
59,5 ± 29,72 
136,25 ± 18,52 
0,39 ± 0,08 
0,715 
0,715 
0,068 
0,068 
0,068 
144,75 ± 24,40 
89,30 ± 6,36 
155,50 ± 65,76 
282,50 ± 144,96 
0,42 ± 0,11 
138,05 ± 22,56 
80,20 ± 10,47 
69,50 ± 23,33 
122,00 ± 29,70 
0,41 ± 0,06 
0,180 
0,180 
0,180 
0,180 
0,655 
ARB  
Valsartan  
(n = 5) 
 
Arg389Arg (n=2) 
  
Arg389Gly/Gly389Gly (n=3) 
 
SBP 
DBP 
LVMI 
LVMass 
RWT 
152,05 ± 18,46 
95,40 ± 9,62 
150,50 ± 34,65 
246,00 ± 65,05 
0,43 ± 0,14 
133,95 ± 5,73 
84,6 ± 8,91 
72 ± 16,97 
119,5 ± 33,23 
0,3 ± 0,17 
0,180 
0,655 
0,180 
0,180 
0,180 
158,97 ± 21,05 
101,17 ± 17,43 
115,33 ± 39,43 
202,67 ± 67,57 
0,73 ± 0,15 
148,97 ± 22,10 
85,70 ± 13,37 
99,33 ± 14,84 
176,00 ± 35,04 
0,59 ± 0,27 
0,593 
0,285 
0,285 
0,285 
0,593 
ARB + 
Beta-blocker 
(n = 11) 
 
Arg389Arg (n=6) 
  
Arg389Gly/Gly389Gly (n=5) 
 
SBP 
DBP 
LVMI 
LVMass 
RWT 
143,13 ± 12,11 
90,20 ± 10,99 
137,50 ± 22,62 
240,17 ± 40,14 
0,49 ± 0,08 
138,15 ± 17,99 
88,22 ± 15,98 
63,67 ± 25,08 
130,67 ± 22,39 
0,36 ± 0,11 
0,753 
0,917 
0,028 
0,028 
0,027 
153,28 ± 20,76 
96,42 ± 14,29 
131,40 ± 48,40 
234,60 ± 97,20 
0,60 ± 0,21 
144,60 ± 20,18 
83,50 ± 11,21 
87,40 ± 22,66 
154,40 ± 41,34 
0,51 ± 0,21 
0,345 
0,080 
0,080 
0,080 
0,500 
 
4. Discussion  
This study identifies the efficacy of  Bisoprolol reducing  left ventricular hypertrophy (LVH) in Arg389Arg 
hypertensive patients receiving ARB. The patients involved in the study were grouped into Arg389Arg or AA 
(18 patients) and Arg389Gly/Gly389Gly or AG/GG (21 patients, where 3 of them in Gly389Gly allele). 
4.1 Role of Arg389Gly Adrenergic Receptor β1 Polymorphism to LVH reduction in Hypertensive Patients 
ADRB1 is the predominant beta-adrenergic receptor expressed on the cardiomyocyte responsive to circulating 
epinephrine and local norepinephrine derived from cardiac sympathetic nerves [29,30]. Previous studies have 
shown that sympathetic nervous activity via ADRB1 regulates numerous physiological events and a wide range 
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of physiological responses, including cardiac chronotropy and inotropy, vascular and smooth muscle tone, and 
carbohydrate and lipid metabolism [31]. Sympathetic nervous activity plays an important role in the 
development of hypertension and its complications [32]. Among the many mechanisms that control cardiac 
function, the stimulation of the frequency and force of contraction by epinephrine and norepinephrine via 
specific beta-adrenergic receptors is the most prominent and, functionally, the most relevant pathway [33]. It is 
well known that nearly 70% of cardiac beta-adrenergic receptors are of the β1-subtype, and the minority are of 
the β2-subtype [34]. In rodents, sustained activation of ADRB1 from infusions of beta-agonists results in 
cardiac hypertrophy [35] and over-expression of ADRB1 in transgenic animals causes progressive 
cardiomyopathy and heart failure [16,35].  
In vitro studies have shown that Arg389 variant of the ADRB1 enhances the β-adrenergic receptor response to 
agonist stimulation compared with Gly389 variant, suggesting that Arg389Gly polymorphism is of functional 
importance. An in vitro study has been shown that the cells transfected with Arg389Gly β1-adrenergic receptor 
show an increase of approximately 200% of β-adrenergic activity in response to agonist stimulation as compared 
with the cell carrying β1 Gly389 receptor [19]. This study showed significantly reduction of  LVMI and 
LVmass in homozygous Arg389  hypertensive patients with LVH receiving ARB.  
The study also showed Gly389 carrier genotype was significantly associated with LV mass reduction response 
to ARB-based treatment in hypertensive patients group with LVH. This was due to the dominant influence of 
alell Arg389 in this study group. This reasoning is supported by data on the number of samples of patients who 
have genotype Gly389Gly in this study only 3 patients from 39 samples (7.69%) with 2 patients in the 
hypertension group with LVH and 1 patient in the non-LVH hypertension group. While the samples were 
Arg389Gly genotype 18 people from 39 samples (46.15%) with 5 patients in the hypertension group with LVH 
(12.82%) and 16 patients in the non-LVH hypertension group (41.02%). 
At the end of the study, 19 patients (48.72%) of 39 samples failed to achieve a blood pressure target of ≤140/90 
mmHg, in which 8 patients with Arg389Arg (AA) genotype were obtained; 10 patients with genotype 
Arg389Gly (AG); and 1 patient with genotype Gly389Gly (GG). Patients who fail to achieve blood pressure 
targets have high adherence levels in taking the drug (evidenced by an MMAS score of 8 at the second follow-
up to the sixth month). So the number of patients who reached the target of blood pressure at the end of the 
study were 20 patients (51.28%). This condition may explain why in the non-LVH hypertension group there was 
an increase in LV mass at the sixth months follow-up period. 
4.2 Relation between Arg389Gly Adrenergic Receptor β1 Polymorphism with Left Ventricular Hypertrophy 
Reduction by Type and Combination of ARB-Based Treatment 
Combination of ARB-based and beta-blocker (Bisoprolol) treatment in Arg389Arg group (wildtype) showed 
significant reduction of LVMI before combination ARB-Bisoprolol 137,50 ± 22.62 g/m2 and after 
administration for 6 months to 63.67 ± 25.08 g/m2 (p = 0.028), as well as the LV mass reduction from 240.17 ± 
40.14 g/m2 to 130.67 ± 22.39 g/m2 (p = 0.01). This significant reduction  in LVMi and LVmass indicates that 
the combination between ARB and Bisoprolol has an effect of  improvement by reducing LVH. It effect caused 
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by the role of Bisoprolol in enhancing the inhibitory effects of both hemodynamic and neurohormonal factors. 
Angiotensin-II receptor blocker (ARB) in systemic will inhibit the effects of worsening of the heart through 
AT1 receptor inhibition pathway and maintain the effect of cardioprotective bond of Angiotensin-II with AT2 
receptor, with the combination of beta-blocker then the bond between β-AR receptors will strengthen barriers 
both at systemic and cardiomyocyte level. 
In a randomized, double-blind trial conducted by Thu¨rmann and his colleagues of  69 patients with untreated 
hypertension and from echocardiography had proven LVH, with left ventricular mass index (LVMi) >134g/m2 
in men and >110g/m2 in women and / or end-diastolic septal thickness >12mm, obtained both angiotensin-II 
receptor blockers (valsartan) and atenolol for 8 months. Echocardiographic data of 58 patients were taken. After 
8 months of getting valsartan (n = 29), the LVMi decrease from 127 ± 23 to 106 ± 25 g /m2 (ratio [R] = 0.83; 
95% CI, 0.79-0.87; P, 0.0001 versus baseline). While with atenolol (n = 29), LVMi decreased slightly, from 127 
± 25 to 117 ± 27 g / m2 (R = 0.92; 95% CI, 0.86 -0.98; P50.0082 versus baseline). The average LVMI reduction 
was about 21 g/m2 with valsartan and only 10 g/m with atenolol (R = 0.91; 90% CI, 0.85 -0.97 versus atenolol) 
[36]. 
This study showes unsignificant reducing LVH in Arg389Arg and Arg389Gly/Gly389Gly hypertensive patient 
receiving ARB (Valsartan or Telmisartan). However, bisoprolol reduce LVH significantly in Arg389Arg 
(wildtype) hypertensive patient receiving ARB but unsignificant LVH reduction in Arg389Gly/Gly389Gly 
(mutation group) hypertensive patients. It was caused by over-expression of Arg389Arg β1-AR, so β1-AR 
blocker (Bisoprolol) reduce LVH effectively in Arg389Arg compare Arg389Gly/Gly389Gly (mutation group).   
5. Conclusion 
Our study shows that ARB treatment for 6-months did not reduce significantly LVMI, LVmass, and RWT in 
both Arg389Arg and Arg389Gly/Gly389Gly hypertensive patients. β1-AR blocker (Bisoprolol) reduce LVH in 
Arg389Arg hypertensive patients receiving ARB significantly. 
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